BioSpace News Archive

CytoMed Therapeutics Limited today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA).

Ginkgo Bioworks and the Government of the Republic of Madagascar today announced that they have entered into a Memorandum of Understanding (“MOU”) with the intent to develop and implement new biosecurity capabilities in Madagascar.

Delta Development Team is thrilled to announce the successful completion of its oversubscribed Series A round, which was led by major investors UAVC and Desert Angels.

ProFound™ Therapeutics today announced the appointment of Klaus Urbahns, Ph.D., as Chief Scientific Officer.

Castle Biosciences, Inc. today announced that the Company will ring the Nasdaq closing bell on Wednesday, Sept. 27, 2023, to raise awareness of melanoma in honor of patients impacted by the disease.

Aviceda Therapeutics announced today multiple upcoming presentations about its lead ophthalmic clinical asset, AVD-104.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and product-specific J-code (J2781) for SYFOVRE ® (pegcetacoplan injection), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration.

XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

Theratechnologies Inc. today announced that it has reached an agreement in principle to amend some of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time (the “Loan Facility”), with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, “Marathon”).

BridgeBio Pharma, Inc. has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 9,167,723 shares of its common stock (Common Stock) at the Friday, September 22, 2023 closing price of $27.27 per share through a private investment in public equity (PIPE) financing.